HIGHLIGHTS
- who: Facioscapulohumeral muscular dystrophy and collaborators from the Hunt`s House, Guy`s Campus, London , UL, UKRadboud University Medical Center, Nijmegen, Netherlands have published the research work: The FSHD muscle-blood biomarker: a circulating transcriptomic biomarker for clinical severity in facioscapulohumeral muscular dystrophy Christopher R. S. Banerji , Anna Greco , Leo A. B. Joosten Baziel G. M. van, in the Journal: (JOURNAL)
- what: The authors propose a complementary approach, based on gene_expression in PT minimally invasive blood samples.
SUMMARY
Losmapimod did not significantly change the primary outcome Page 5 of 47 measure . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.